ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux
- Interventions
- Registration Number
- NCT00820079
- Lead Sponsor
- Addex Pharma S.A.
- Brief Summary
Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- diagnosis of typical GERD
- well controlled on a standard clinical symptoms controlled dose of PPI treatment
- body mass index ≤32 kg/m2
Exclusion Criteria
- exclusively atypical symptoms of GERD
- symptoms that have been shown not to be associated with GERD
- erosive oesophagitis
- hiatus hernia > 3 cm
- current diagnosis of co-existing psychiatric disease
- known clinically significant allergy or known hypersensitivity to drugs
- pregnant or breast-feeding
- has received sodium valproate or topiramate within 30 days of Screening
- has a history of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ADX10059 120 mg ADX10059 Twice-daily ADX10059 Matching Placebo ADX10059 Matching Placebo twice-daily
- Primary Outcome Measures
Name Time Method Number of GERD symptom free days in week 2 of study medication treatment 2 weeks
- Secondary Outcome Measures
Name Time Method GERD symptoms 2 weeks Sleep disturbance 2 weeks Use of antacid rescue medication 2 weeks Global assessment of GERD 2 weeks Effect on lower oesophageal sphincter and reflux episodes 2 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ADX10059's efficacy in GERD symptom control via mGluR5 modulation?
How does ADX10059's therapeutic effect compare to proton pump inhibitors in Phase 2B GERD trials?
Which biomarkers correlate with response to mGluR5 negative allosteric modulators in NCT00820079?
What adverse events are associated with ADX10059 in Phase 2 trials and how are they managed?
Are there combination therapies or competitor drugs targeting mGluR5 for GERD treatment development?
Trial Locations
- Locations (11)
Wien
🇦🇹Wien, Austria
Leuven
🇧🇪Leuven, Belgium
Bordeaux
🇫🇷Bordeaux, France
Lyon
🇫🇷Lyon, France
Nantes
🇫🇷Nantes, France
Berlin
🇩🇪Berlin, Germany
Dresden
🇩🇪Dresden, Germany
Gorlitz
🇩🇪Gorlitz, Germany
Leipzig
🇩🇪Leipzig, Germany
Madgeburg 12
🇩🇪Magdeburg, Germany
Scroll for more (1 remaining)Wien🇦🇹Wien, Austria